A pre-planned feasibility analysis (based on run-in data from 2253 participants across all tumour cohorts), suggested that aspirin is well-tolerated after radical therapy, with a low burden of toxicity across all tumour groups (13/2253, 0.6% had CTCAE grade 3/4 symptoms). This data has now been published in The Lancet Gastroenterology and Hepatology and can be found here: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(19)30289-4/fulltext
Contact Details
If you are an individual who is interested in taking part in Add-Aspirin, please talk to your doctor who will be able to consider whether you are suitable for the trial.
For healthcare professionals
Please log into the members area for Add-Aspirin contact details.
Register Interest
For healthcare professionals
If your centre would like to recruit participants to Add-Aspirin, contact us:
mrcctu.add-aspirin@ucl.ac.uk
From Monday 16th March 2020, to RANDOMISE a participant in the UK please call +44 (0)20 7670 4925, rather than the usual randomisation line.
To RANDOMISE a participant from Republic of Ireland or India only, please use the 'Register a participant' link above to randomise online. Please make sure to press 'Randomise' once logged in to the server.
Unblind a participant in the UK